L22- GIT Drugs I (anti-emetics) Flashcards
list the many anti-emetic drug categories
- H1 antagonist
- D2 antagonist
- antimuscarinics
- 5HT-3 antagonists
- NK1 antagonists
- corticosteroids
- benzodiazepines
- cannabinoids
list the H1 antagonists + indications
diphenydramine
meclizine
cyclizine
motion sickness, postoperative emesis
describe MOA of H1 antagonist + indications
- blocks signals from vestibular afferents as well as from brainstem
- motion sickness, postoperative emesis
list the D2 antagonists + indication
- promethazine
- droperidol
-motion sickness
(no CINV uses)
D2 antagonist MOA and AEs
MOA: antagonism at CTZ (chemoreceptor trigger zone)
AE: extrapyramidal effects
(1) is the main antimuscarinic used as an anti-emetic in (2) situations.
1- scopolamine
2- motion sickness, some postoperative n/v
(not first line choice for CINV)
CINV =
chemotherapy induced nausea and vomiting
CINV:
- (1) is the most associated drug
- (2) first phase
- (3) second phase
1- cisplatin
2- Acute: w/in 24hrs, universally experienced by patients
3- Delayed phase (days 2-5), only affects some patients
list the 5-HT3 antagonists
ondansetron (prototype)
granisetron
list the target sites for 5-HT3 antagonists
- vagal afferents
- STN
- CTZ
- AP
list the uses of 5-HT3 as anti-emetic (include AEs)
- prophylaxis against acute CINV (drug of choice)
- hyperemesis gravidarum (pregnancy)
- not good for delayed CINV, motion sickness
- well-tolerated
(1) is the NK1 antagonist, which function as (2) and are used for (3).
NK1- neurokinin
1- Aprepitant / fosaprepitant (parenteral formulation)
2- NK receptor antagonist for substance P
3- prophylaxis against delayed CINV (caused by moderate / highly emetogenic drugs)
NK1 antagonists are administered with (1) and has a (2) effect on metabolism.
1- dexamethasone, 5-HT3 antagonist
2- metabolized by CYP3A4 –> affecting warfarin and oral contraceptives
list the corticosteroids + indications
- dexamethasone
- methylprednisolone
-CINV, in adjunct
describe MOA of corticosteroids + indications
- suppresses periumoral inflammation and PG production
- CINV, in adjunct